This technology features a pharmaceutical composition and health functional food for preventing and treating obesity, using a peptide of 12 to 17 amino acids centered on the sequence of SEQ ID NO: 5 as the active ingredient. The peptide consists of SEQ ID NO: 5 itself or a form with H or HH added to the C-terminus and Y, YF, or YFR added to the N-terminus, either individually or in combination.
Obesity is a disease associated with complications such as cardiovascular disease, hypertension, and dyslipidemia. Recently, sarcopenic obesity—where muscle loss leads to a lower basal metabolic rate and subsequent fat gain—has been on the rise, yet effective treatments remain scarce. Previous anti-obesity drugs like fenfluramine were withdrawn due to pulmonary hypertension and heart valve lesions, sibutramine due to cardiovascular side effects, and orlistat causes gastrointestinal discomfort and inhibits fat-soluble vitamin absorption, highlighting a lack of fundamental, side-effect-free treatments.
This technology includes a peptide in the form of SEQ ID NO: 6 with both ends extended. This peptide suppresses appetite by lowering the expression of hypothalamic orexigenic factors AgRP and NPY, and increases energy expenditure by enhancing UCP-1 expression in adipose tissue. It prevents fat accumulation in adipocytes and promotes lipolysis while simultaneously stimulating muscle biosynthesis and inhibiting muscle atrophy. It can be applied to treatments for sarcopenic obesity, health functional foods for weight management and muscle maintenance in the elderly, and protein supplements to prevent muscle loss during dieting, effectively breaking the yo-yo cycle caused by metabolic decline after weight loss.
CN117858716A, EP4364749A1, US2024-0342238A1, WO2023-277507A1
